Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 ChinaThird Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Tongji Medical College Huazhong University of Science and Technology Taiyuan 030032 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Tongji Medical College Huazhong University of Science and Technology Taiyuan 030032 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
Department of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China;
relapsed or refractory multiple myeloma; chimeric antigen receptor T-cell therapy; impaired renal function; B cell maturation antigen;